Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
December 2020
November 2020
-
In The News
Enabling a stable supply of medicines during COVID-19
What are the key factors ensuring Novartis supply chains remain operational during the pandemic? -
Featured News
Meet Novartis Management 2020
Annual meeting highlights progress on the company’s transformation and growth strategy. -
Key Release
Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event
Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth… -
Story Discovery
New hope for treating inflammatory diseases of the kidney
Novartis researchers aim to preserve kidney function – and quality of life – for patients.
-
Media Release
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other… -
Media Release
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIsELARA results for Kymriah® in relapsed or… -
Story Discovery
Predictive analytics could bring medicines to patients faster
Novartis researchers are using data to accelerate drug development.
-
Featured News
Achieving 100% renewable electricity
Five virtual power purchase agreements with three developers expected to add more than 275 megawatts of clean power to the electrical grid.
-
Media Release
Novartis set to achieve 100% renewable electricity in its European operations
Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical gridProjects expected to address Novartis greenhouse gas… -
Story Discovery
Making Possible: Stepping toward a future with cell and gene therapy
These stories offer a glimpse into the lives of people touched by a new era of medicine.
-
Featured News
Leading performance in sustainability
Novartis included in Dow Jones Sustainability World Index, with industry-leading performance in environmental and social reporting and human capital.